• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tenax Therapeutics, Inc. - Common Stock (NQ:TENX)

    2.320 +0.470 (+25.41%)
    Official Closing Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Tenax Therapeutics, Inc. - Common Stock

    News headline image
    TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX)
    From Levi & Korsinsky, LLP
    Via Business Wire
    Tenax Therapeutics Inc. (NASDAQ: TENX) Near the Top of Equities by Percentage Gain on 2/6
    Via Investor Brand Network
    InvestorNewsBreaks – Tenax Therapeutics Inc. (NASDAQ: TENX) Announces $15.6M Public Offering
    Via Investor Brand Network
    News headline image
    Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
    Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and 
    Via Spotlight Growth
    Topics Intellectual Property
    News headline image
    Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    NASDAQ:TENX Shareholder Alert: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc. ↗
    San Diego, CA -- (SBWIRE) -- 02/17/2022 -- Certain directors of Tenax Therapeutics, Inc. are under investigation concerning potential breaches of fiduciary duties . 
    Via SBWire
    News headline image
    Investigation for Investors in Tenax Therapeutics, Inc. (NASDAQ:TENX) Shares Announced ↗
    San Diego, CA -- (SBWIRE) -- 12/13/2021 -- An investigation was announced for investors of Tenax Therapeutics, Inc. (NASDAQ:TENX) shares over potential securities laws violations by Tenax Therapeutics,... 
    Via SBWire
    News headline image
    NASDAQ:TENX Investor Notice: Investigation over Potential Wrongdoing at Tenax Therapeutics, Inc. ↗
    San Diego, CA -- (SBWIRE) -- 12/01/2021 -- Certain directors of Tenax Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
    Via SBWire
    News headline image
    Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    NASDAQ:TENX Investor Notice: Investigation over Possible Securities Laws Violations by Tenax Therapeutics, Inc. ↗
    San Diego, CA -- (SBWIRE) -- 11/09/2021 -- Tenax Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
    Via SBWire
    News headline image
    Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH)
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Set to Join Russell Microcap® Index
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial ”
    From Tenax Therapeutics, Inc.
    Via Business Wire
    News headline image
    Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders
    From Tenax Therapeutics, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.